Abstract:BACKGROUND Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) has had a significant increase over the past 4 decades. The pathophysiological role of the cyclooxygenase-2 (cox-2) gene and factors responsible for the expression in GEP-NETs is of clinical value. Current study determined the expression of cox-2 gene in human GEP-NET tissues and corresponding cell lines, investigated the molecular mechanisms underlying the regulation of cox-2 gene expression and assessed the effect of nonsteroidal anti-inflammatory drugs (NSAIDs) on both anchorage-dependent and independent growth of GEP-NET cells. MATERIAL AND METHODS GEP-NET tissues and QGP-1, BON, and LCC-18 GEP-NET cell lines were used. The expression of cox-2 gene was analyzed by immunohistochemistry, western blot, RT-PCR, and enzyme immunoassay. Transient transfection and luciferase assays along with electrophoretic mobility shift assays were conducted to explore the regulation of cox-2 gene expression. The effect of COX-inhibitors on GEP-NET cell growth was determined by proliferation assays and colony growth assessment. RESULTS We found 87.8% of GEP-NET tissues stained positive for COX-2. QGP-1 and LCC-18 cells expressed cox-2 gene. PGE2 (prostaglandin E2) amounts quantified in the supernatants of NET cells matched to cox-2 expression level. The CRE-E-box element (-56 to -48 bp) and binding of USF1, USF2, and CREB transcription factors to this proximal promoter element were essential for cox-2 promoter activity in GEP-NET cells. COX-2-specific inhibitor NS-398 potently and dose-dependently inhibited PGE2 release from QGP-1 cells. Interestingly, both NS-398 and acetylic salicylic acid effectively suppressed proliferation of QGP-1 and BON cells in a dose-dependent manner. CONCLUSIONS The majority of GEP-NETs over express cox-2 gene. The binding of CREB and USF-1/-2 transcription factors to a proximal, overlapping CRE-Ebox element is the underlying mechanism for cox-2 gene expression. NSAIDs potently suppressed the proliferations and may offer a novel approach for chemoprevention and therapy of GEP-NETs.

Cyclooxygenase-2 in glioblastoma multiforme.

Expression of cyclooxygenase-2 (COX-2) in human astrocytoma

Expression of cyclooxygenase-2 and VEGF in human glioma and its role

Pleiotropic effects of the COX-2/PGE2 axis in the glioblastoma tumor microenvironment

Prostaglandin E2 Signaling: Alternative Target for Glioblastoma?

Small-molecule Inhibition of Prostaglandin E Receptor 2 Impairs Cyclooxygenase-Associated Malignant Glioma Growth.

Cyclo-Oxygenase 2 Up-Regulates the Effect of Multidrug Resistance

Cyclooxygenase-2 inhibitors induce anoikis in osteosarcoma via PI3K/Akt pathway.

Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity.

Relationship of Cyclooxygenase-2 with Vascularization and Proliferation and Invasion in Human Glioma

Clinicopathological and prognostic significance of COX-2 in glioma patients: a meta-analysis

Effects of Cyclooxygenase-2 in Tumor Invasion and Metastasis and Treatment

Involvement of Cyclooxygenase-2 in Establishing an Immunosuppressive Microenvironment in Tumorspheres Derived from TMZ-Resistant Glioblastoma Cell Lines and Primary Cultures

Parecoxib Inhibits Glioblastoma Cell Proliferation, Migration and Invasion by Upregulating Mirna-29C.

Complementary roles of EP2 and EP4 receptors in malignant glioma

Identification of Cytochrome P450 2E1 as a Novel Target in Glioma and Development of Its Inhibitor as an Anti‐Tumor Agent

Expression and Molecular Regulation of the Cox2 Gene in Gastroenteropancreatic Neuroendocrine Tumors and Antiproliferation of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma

Expression and Its Significance of Cyclooxygenase-2 in Human Astrocytoma

Effects of cyclooxygenase-2 inhibitor on proliferation and apoptosis of C6 glioma cells

Structural Requirements of Benzodiazepines for the Inhibition of Pig Brain Nitric Oxide Synthase.